TITLE:
Evaluation of Insulin Resistance Indices in Type 2 Diabetic Patients Treated with Different Anti-Diabetic Drugs
AUTHORS:
Mohammad-Ali Ghaffari, Seyedeh-Arefeh Payami, Seyed-Peyman Payami, Damoon Ashtary-Larky, Abdolrahim Nikzamir, Ghorban Mohammadzadeh
KEYWORDS:
Type 2 Diabetes, Insulin Resistance, HOMA-IR, QUICKI, 20/(Fasting C-Peptide × Fasting Plasma Glucose)
JOURNAL NAME:
Open Journal of Endocrine and Metabolic Diseases,
Vol.6 No.2,
February
16,
2016
ABSTRACT: Clinically, determination
of insulin resistance is important for diabetic patients. We evaluated the
relationship among 20/(fasting C-peptide × fasting plasma glucose), HOMA-IR and
QUICKI indices in type 2 diabetic patients. The study included 40 patients with
type 2 diabetes. Patients divided into three groups based on their medication:
metformin, metformin + glibenclamide and metformin + glitazone. Fasting blood
sugar, and lipid profile were measured by enzymatic method, serum insulin, and
C-peptide were measured by ELISA method. Insulin resistance was calculated by
using of 20/(fasting C-peptide × fasting plasma glucose), HOMA-IR and QUICKI
indices. There was no significant relationship between 20/(fasting C-peptide ×
fasting plasma glucose) index and other parameters in all studied groups except
QUICKI in metformin group showed a significant correlation with 20/(fasting
C-peptide × fasting plasma glucose) index (r = 0.56 and p = 0.03). There was a
significant correlation between HOMA-IR and QUICKI indices in all studied
groups. There was no significant relationship between 20/(fasting C-peptide ×
fasting plasma glucose) index with other clinical parameters. On the other
hand, our data strongly suggested a significant correlation between HOMA-IR and
QUICKI indices in studied subjects with type 2 diabetes.